H.I.G. Europe to Acquire Meyra Group and Alu Rehab to Form Leading Mobility Equipment Manufacturer in Europe
24.10.2019 14:57:00 EEST | Business Wire | Press release
H.I.G. Capital ("H.I.G."), a leading global private equity investment firm with over EUR 31 billion of equity capital under management, is pleased to announce that an affiliate has signed definitive agreements to acquire Meyra Group S.A. and Alu Rehab A/S. With the support of H.I.G., both companies will combine to form a new leading mobility equipment manufacturer in Europe. The transaction is subject to clearing by the relevant antitrust authorities with closing anticipated by end of 2019.
Meyra Group S.A. (“Meyra”) designs, manufactures and sells active and e-powered wheelchairs, rehabilitation equipment and orthopedics. The company is among the market leaders within the segment of premium, technologically advanced wheelchairs for active users and sells its products worldwide under the iconic “Meyra” brand since 1936. With manufacturing, assembly and distribution sites in Germany and Poland, Meyra has approximately 600 employees and is expected to generate more than EUR 80 million in sales in 2019.
Alu Rehab A/S (“Alu Rehab”) is a comfort wheelchair specialist, which was established in 1989 and sells its products under the well-known “Netti” brand. The company’s multifunctional comfort wheelchairs, specialized seating systems and equipment are designed to support customers in their daily lives by tailoring solutions to individual needs. Alu Rehab has manufacturing, assembly and distribution facilities in Norway, Denmark and China and has approximately 120 employees.
Together, both companies will form a new leading mobility equipment manufacturer in Europe and are highly complementary with synergies across the entire value-chain from manufacturing, logistics, assembly to sales and services. The current management teams of both companies will continue to run the group going forward. The combined group will generate over 40% of its sales in the attractive German-speaking healthcare market. Going forward, the new group will further grow in currently underrepresented European countries and selected markets outside Europe, organically and through focused acquisitions.
Michał Perner, President of the Management Board and founding shareholder of Meyra, commented: “Meyra is a very strong brand that has continuously expanded its market position due to superior quality of products and reliable services. We are delighted to partner with H.I.G., who will support us to tap the substantial additional potential of the company and the market we are operating in.”
Kjetil Gausel, CEO of Alu Rehab, commented: “For Alu Rehab, joining with Meyra will open attractive opportunities as we significantly expand our product portfolio and geographic reach. We are convinced that our unique Netti seating system in combination with Meyra’s high-quality active and e-powered wheelchair bases will generate substantial additional demand for the group.”
Holger Kleingarn, Managing Director at H.I.G., commented: “The combination of Meyra and Alu Rehab represents a strong strategic and cultural fit. We look forward to the partnership with Michał, Kjetil and their teams and to supporting them in the group’s international expansion, both organically and by acquisition.”
About H.I.G. Capital
H.I.G. is a leading global private equity and alternative assets investment firm with over EUR 31 billion of equity capital under management.* Based in Miami, and with offices in New York, Boston, Chicago, Dallas, Los Angeles, San Francisco, and Atlanta in the U.S., as well as international affiliate offices in London, Hamburg, Madrid, Milan, Paris, Bogotá, Rio de Janeiro and São Paulo, H.I.G. specializes in providing both debt and equity capital to small and mid-sized companies, utilizing a flexible and operationally focused / value-added approach:
- H.I.G.’s equity funds invest in management buyouts, recapitalizations and corporate carve-outs of both profitable as well as underperforming manufacturing and service businesses.
- H.I.G.’s debt funds invest in senior, unitranche and junior debt financing to companies across the size spectrum, both on a primary (direct origination) basis, as well as in the secondary markets. H.I.G. is also a leading CLO manager, through its WhiteHorse family of vehicles, and manages a publicly traded BDC, WhiteHorse Finance.
- H.I.G.’s real estate funds invest in value-added properties, which can benefit from improved asset management practices.
Since its founding in 1993, H.I.G. has invested in and managed more than 300 companies worldwide. The firm's current portfolio includes more than 100 companies with combined sales in excess of EUR 27 billion. For more information, please refer to the H.I.G. website at www.higcapital.com.
* Based on total capital commitments managed by H.I.G. Capital and affiliates.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191024005500/en/
Contact information
Dr. Holger Kleingarn
Managing Director
hkleingarn@higcapital.com
H.I.G. European Capital Partners GmbH
P: +49 40 41 33 06 100
www.higcapital.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yoshihiro Shimamura Joins the Marché du Film’s “Investors Circle 2026” as an Invited Investor, Backing a New Feature Film17.7.2026 04:00:00 EEST | Press release
Shimamura Yoshihiro Film Production Co., Ltd. (Head office: Osaka, Japan; Representative Director: Yoshihiro Shimamura), a company active in film production and investment, today announced that Representative Director Yoshihiro Shimamura has decided to invest in an international feature film after being invited to the “Investors Circle 2026” — a distinction that reflects his standing as one of the field’s most highly regarded producers and investors. Hosted by the Marché du Film, the business arm of the Festival de Cannes and one of the world’s largest film markets, the Investors Circle is an invitation-only summit that connects a select group of private investors with high-end feature films during early-stage financing. Held in Cannes, France, May 16-17, 2026, it brings internationally acclaimed directors and producers together with investors around a curated slate of projects in development. During the summit, Shimamura attended private pitching sessions and, after individual meeting
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe ’s Coverage of ESCMID Global Congress 202617.7.2026 04:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies17.7.2026 01:00:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK) announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279), a next-generation, highly selective and potent oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented at the 2026 American Academy of Dermatology (AAD) Innovation Academy, these secondary endpoint data show that zasocitinib demonstrated consistent and high rates of skin clearance across hard-to-treat, high-impact sites, including the scalp, nails, palms and soles, compared with placebo.1-5 These data build on the topline results from the Phase 3 randomized, multicenter, double-blind, placebo- and active comparator-controlled LATITUDE PsO 3001 and 3002 studies.2,6 In those studies, about 70% of patients treated with zasocitinib achieved static Physician Global Assessment (sPGA) 0/1 (clear or almost clear skin) at week 16, with a significantly greater Psoriasis Area and Severity Index (PASI) 75 response rate seen as early as w
Merz Completes Inaugural €450 Million Schuldschein Loan Issuance17.7.2026 00:36:00 EEST | Press release
The Merz Group has successfully completed its first-ever Schuldschein loan issuance, placing a total volume of €450 million in the debt capital market – a multiple of three relating to the launch volume. The debut transaction was significantly oversubscribed and attracted strong interest from all investor groups. The proceeds were settled and paid out today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716926041/en/ Dr. Almuth Steinkühler, Chief Financial Officer Merz Group The transaction comprises both fixed- and floating-rate tranches with maturities of three, five, seven, and ten years. Around 50 German and international investors participated, representing a broad range of institutions, including private banks, German federal state-owned banks, public savings banks, cooperative banks, pension funds and occupational pension institutions. With the successful placement, Merz has further diversified its funding base by
The Estée Lauder Companies Appoints Madeleine Boyd as Senior Vice President, Global Brand Communications16.7.2026 23:22:00 EEST | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced the appointment of Madeleine Boyd as Senior Vice President, Global Brand Communications, effective July 20, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260716738393/en/ Photo by Esteban La Tessa As part of the company’s continued efforts to strengthen how its brands better connect with consumers, Ms. Boyd will establish and lead a newly integrated Global Brand Communications team. In this role, she will ensure the company’s diverse portfolio is anchored by a cohesive enterprise communications strategy, while accelerating bold, consumer-first storytelling that drives earned media, cultural relevance, and brand desirability. She will also strengthen creator engagement, helping the company’s brands gain attention where culture is being shaped. Ms. Boyd brings extensive experience spanning brand strategy, communications, consumer engagement, and cultural insight
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
